▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / MIRM

MIRM — Mirum Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1759425 ·
Last close
$99.35
Market Cap
$6.06B
52W High
$114.99
52W Low
$84.94
ADV30
1,083,757
Next earnings
2026-08-05
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 159,882,000 131,077,000 -63,163,000 -790,155,000 890,916,000 324,907,000 648,422,000
Dec 2025 148,932,000 120,668,000 -4,567,000 -5,730,000 842,813,000 296,683,000 528,123,000
Sep 2025 133,010,000 107,473,000 2,603,000 2,905,000 785,115,000 282,021,000 493,069,000
Jun 2025 127,785,000 104,364,000 -4,989,000 -5,861,000 725,825,000 228,122,000 470,667,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-170,975,000
Investing CF
$-19,389,000
Financing CF
$303,862,000
CapEx
$-11,577,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.61
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,457,699,000
Inventory
$25,518,000
Receivables
$133,113,000
ST Investments
$61,352,000
EBIT TTM
$-783,050,000
Pretax Income TTM
$-797,459,000
Interest Exp TTM
$14,409,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$569,609,024
EBITDA
$-50,050,000
Free Cash Flow
$166,895,872
Enterprise Value
$5,995,700,224
Total Cash
$386,259,008
Total Debt
$323,779,008
Shares Out
60,981,227
Trailing EPS
$-13.60
Book Value
$3.98
ROE
-335.8%
ROA
-5.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 521,312,000 -22,136,000 -23,363,000 842,813,000 528,123,000 — 55,827,000
Dec 2024 336,888,000 -87,606,000 -87,942,000 670,754,000 445,114,000 — 10,325,000
Dec 2023 186,374,000 -109,154,000 -163,415,000 646,621,000 397,951,000 — -70,944,000
Dec 2022 77,062,000 -131,220,000 -135,665,000 352,906,000 210,869,000 — -120,136,000

TTM Snapshot

Revenues TTM
$138,102,000
NetIncome TTM
$-37,823,000
OpCashFlow TTM
$0
Assets (Latest)
$670,754,000
Forward EPS
$-0.09

Max Pain — expiry 2026-06-18

max pain strike: $100.00 · spot: $101.00 · call oi: 1,045 · put oi: 220
Expected Move to 2026-06-18: ±$12.50 (12.38%) — implied range $88.50 – $113.50 · ATM straddle on $100.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RYTM RHYTHM PHARMACEUTICALS, INC. $6.06B $88.38 —
CNTA Centessa Pharmaceuticals plc $6.15B $39.72 —
PTCT PTC THERAPEUTICS, INC. $6.23B $75.14 —
LQDA Liquidia Corp $6.33B $71.23 —
COGT Cogent Biosciences, Inc. $5.66B $33.10 —

News headlines (Yahoo Finance, 1h cache)

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
2026-06-15 14:43 · Yahoo
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
2026-06-14 20:35 · Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-11 20:01 · Yahoo
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
2026-06-05 15:30 · Yahoo
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
2026-06-04 12:05 · Yahoo
Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress
2026-06-04 09:06 · Yahoo
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
2026-05-30 16:00 · Yahoo
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
2026-05-28 20:27 · Yahoo
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
2026-05-27 11:09 · Yahoo
Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM)
2026-05-25 16:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →